Talha Badar/X
Jun 16, 2025, 18:24
Talha Badar: TKI Selection Based on Mutation Profiles in CML at EHA 2025
Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared a post on X:
“Emergence of ASXL1 and tyrosine kinase domain mutation with different TKI; imatinib, 2nd generation TKI and asciminib. Best choice of TKI with respect to mutation.”
More posts featuring EHA 2025.
-
Oct 3, 2026, 00:25Antiplatelets May Be a Strong Option After Ischemic Stroke in Active Cancer – International Journal of Stroke
-
Oct 3, 2026, 00:24Mavis Agnes Kisakye: Honored to Join UNHLS Leadership in Advancing HIV Diagnostics in Uganda
-
Oct 3, 2026, 00:23Phil Spinella: Blood is for Bleeding, Salt Water is for Cooking pasta, Keeping it simple
-
Oct 3, 2026, 00:21Pablo Corral: The ANGPTL Axis in Dyslipidemia and Cardiovascular Risk
-
Oct 3, 2026, 00:20Raghavendra Rao: The Link Between Chronic Venous Disease and VTE May Be Less Robust Than Previously Thought
-
Oct 3, 2026, 00:19Nicolas Hubacz: Immune Cells in the Embryo
-
Oct 3, 2026, 00:18Kalpana Gupta Shekhawat: Reading Beyond the Numbers – A Deeper Look at Routine Blood Reports
-
Oct 3, 2026, 00:17Paulus Kirchhof: Aortic stiffness – A Consequence of High Blood Pressure, or a Driver, or Both?
-
Oct 3, 2026, 00:17Konstantin Yenkoyan: When Science Steps Outside the Laboratory – ERNA 2026